Sientra (NASDAQ:SIEN) – William Blair issued their Q1 2018 earnings per share (EPS) estimates for Sientra in a research report issued on Wednesday, March 14th, according to Zacks Investment Research. William Blair analyst M. Kaczor expects that the medical instruments supplier will earn ($0.89) per share for the quarter. William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Sientra’s Q2 2018 earnings at ($0.71) EPS, Q3 2018 earnings at ($0.60) EPS, Q4 2018 earnings at ($0.53) EPS, FY2018 earnings at ($2.67) EPS, Q1 2019 earnings at ($0.63) EPS, Q2 2019 earnings at ($0.51) EPS, Q3 2019 earnings at ($0.60) EPS, Q4 2019 earnings at ($0.51) EPS and FY2019 earnings at ($2.26) EPS.
Several other equities analysts also recently issued reports on the company. Lake Street Capital downgraded Sientra from a “buy” rating to a “hold” rating and cut their price objective for the company from $15.00 to $11.00 in a research report on Wednesday, February 21st. Stifel Nicolaus raised Sientra from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Friday, January 19th. BidaskClub cut Sientra from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Zacks Investment Research cut Sientra from a “buy” rating to a “hold” rating in a research note on Saturday, March 17th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $19.00 target price on shares of Sientra in a research note on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $13.50.
SIEN traded down $0.09 during trading on Friday, hitting $9.26. The company’s stock had a trading volume of 157,654 shares, compared to its average volume of 214,195. Sientra has a 12 month low of $7.20 and a 12 month high of $16.68. The company has a market cap of $183.67, a price-to-earnings ratio of -3.28 and a beta of -1.06.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings data on Tuesday, March 13th. The medical instruments supplier reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.21). Sientra had a negative net margin of 175.22% and a negative return on equity of 107.35%. The business had revenue of $11.10 million during the quarter, compared to the consensus estimate of $11.90 million. During the same quarter in the previous year, the firm posted ($0.43) EPS. The company’s revenue for the quarter was up 70.8% compared to the same quarter last year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in SIEN. BlackRock Inc. grew its stake in shares of Sientra by 4.9% during the fourth quarter. BlackRock Inc. now owns 758,512 shares of the medical instruments supplier’s stock worth $10,664,000 after purchasing an additional 35,429 shares during the period. Vanguard Group Inc. grew its stake in shares of Sientra by 11.2% during the second quarter. Vanguard Group Inc. now owns 590,311 shares of the medical instruments supplier’s stock worth $5,737,000 after purchasing an additional 59,546 shares during the period. Bamco Inc. NY grew its stake in shares of Sientra by 6.4% during the third quarter. Bamco Inc. NY now owns 501,500 shares of the medical instruments supplier’s stock worth $7,723,000 after purchasing an additional 30,000 shares during the period. Senzar Asset Management LLC grew its stake in shares of Sientra by 271.6% during the fourth quarter. Senzar Asset Management LLC now owns 484,607 shares of the medical instruments supplier’s stock worth $6,814,000 after purchasing an additional 354,200 shares during the period. Finally, Schroder Investment Management Group grew its stake in shares of Sientra by 1.1% during the third quarter. Schroder Investment Management Group now owns 437,276 shares of the medical instruments supplier’s stock worth $6,730,000 after purchasing an additional 4,815 shares during the period. 77.38% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Sientra (NASDAQ:SIEN) to Post Q1 2018 Earnings of ($0.89) Per Share, William Blair Forecasts” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/analysts-offer-predictions-for-sientra-incs-q1-2018-earnings-sien.html.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Get a free copy of the Zacks research report on Sientra (SIEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.